Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
Details : Moxetumomab Pasudotox is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in clinical studies for the treatment of Leukemia, Hairy Cell.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 18, 2018
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Marrow Donor Program | Pediatric Blood and Marrow Transplant Consortium | MedImmune | St. Baldrick's Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moxetumomab Pasudotox is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 14, 2015
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Marrow Donor Program | Pediatric Blood and Marrow Transplant Consortium | MedImmune | St. Baldrick's Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moxetumomab Pasudotox is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 27, 2014
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moxetumomab Pasudotox is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 03, 2013
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Details : Moxetumomab Pasudotox is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Hairy Cell.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 11, 2013
Lead Product(s) : Moxetumomab Pasudotox
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
